About Peptide Empire
A small publication about a field with very large ambitions.
Why an empire
The name suits a field that keeps adding territory. A hormone analogue enters a new disease trial. A peptide with an immune history acquires a reputation for resilience. A coenzyme gets welcomed into the same conversation despite having different chemistry. The word “peptide” begins to stand for almost every hoped-for improvement.
I admire the expansion that semaglutide’s kidney study actually tested. CJC-1295’s much wider reputation prompts a different reaction: impatience to test the claims. A result can deserve admiration and still leave most of the grander claims unanswered.
My patience stretches further for an ambitious experiment than for an ambitious adjective. “Anti-aging” can encompass almost anything; a study of muscle insulin sensitivity has a definite question and an outcome that can be examined. I can get somewhere with that smaller result.
What is here
Peptide Empire publishes essays on semaglutide, thymosin alpha-1, CJC-1295, NAD+ and PT-141, with a catalogue for comparison and a reading list. The subjects share a surrounding conversation more readily than they share a clinical purpose. That unevenness is why they are worth putting beside one another.
This is a publication, with no product checkout, dispensing service or appointments. Nothing on these pages can examine a symptom, account for someone’s medicines or decide whether a treatment fits their history. The essays are not medical advice. Individual care calls for a qualified health professional who can do that work.
The possibility of a useful treatment interests me. So does the possibility that an appealing explanation fails when the trial gets larger. Both conclusions deserve space here, without turning every compound into either a hero or a cautionary tale.
Corrections
A wrong participant count or a missing qualification can alter an argument. The contact page gives the address for a correction, along with the information needed to check it. The source list contains the papers behind the clinical and biological findings. Published claims can improve when the evidence demands it.